A shadow market for unlicensed slimming medications is being driven by social media fitness personalities and vendors on messaging platforms, according to recent findings.
Experimental Treatment Gaining Traction Online
Retatrutide, which is still in research studies, is being advertised by online personalities for its alleged fat-burning effects. Followers are urged to message these profiles privately for supplier links, while also receiving promotional offers.
Active Trade on Messaging Platforms
Separately, a robust trade exists on Telegram, where communities with numerous of participants share comparison images, administration instructions and claims of rapid UK delivery. Sellers promote the drug there before redirecting buyers to other platforms for transactions.
Understanding Retatrutide
Retatrutide is an experimental injectable developed by US drugmaker Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist patients lose up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed online as the next Ozempic.
Medical Experts Voice Worries
However, doctors and pharmacists have warned that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could result in users injecting substances of uncertain source.
Some professionals stated the demand for retatrutide could be connected to the increasing cost of approved slimming treatments such as Mounjaro.
Legal Status and Implementation
Marketing the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be promoted or supplied for personal consumption under the British medical regulations.
Some influencers attempt to circumvent the rules by calling to the substance as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted drug, but promotion and distribution can still breach medicines, advertising, and customer regulations, risking penalties, prosecution or imprisonment.
Platform Response and Material Removal
Based on TikTok, the platform has removed problematic material and prohibited related keywords and search suggestions. The company said it was dedicated to keeping the service secure and allocating resources in strengthening compliance measures.
Online Trading Operations
Research also found communities with up to 9,000 members marketing the experimental drug using Telegram's integrated search feature, which operates like a public directory. Entering “retatrutide” instantly displays channels with thousands of members, populated with images of slimming results, glowing testimonials and step-by-step instructions for mixing or injecting at residence.
Within moments of entering one community, a seller posted WhatsApp details, where the majority of purchases take place. The vendor sent an instruction manual and promised shipping within two days. When questioned whether the substance was authentic, one vendor responded: “You can’t be sure.” Another shared a photo of a supposed testing documentation. None inquired about weight, medical conditions or past usage.
Product Information and Costs
Inside these communities, posts display black plastic parcels with Royal Mail stickers, stating to contain fresh supplies. One communication stated: “It took eight of us to load them this morning.”
Customers can select between powder vials, mixed at home with sterile water, or pre-filled pens usually priced at £160 for 20mg. When questioned how long a injector should last, sellers give contradictory responses ranging from a few weeks to “depends on your body”.
Service Oversight and Security Measures
A spokesperson for Telegram said it regularly moderated dangerous material on its platform including material that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.
Healthcare Expert Warnings
“Individuals are injecting materials they cannot confirm. Even if the science behind this drug is valid, these online products may not include what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.
Dr Crystal Wyllie of an online medical service linked the increase in interest to current cost increases for authorized weight-loss drugs such as Mounjaro. “With costs increasing, patients are using online platforms. But fake injections are highly risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she explained.
Her team has already encountered individuals injured by self-injection from unconfirmed sources. “We recognize the frustration, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said Wyllie. “These substances could be impure or incorrectly dosed.”
Manufacturer Position
A spokesperson from Eli Lilly stated the substance was in phase 3 clinical trials and had not been evaluated or approved by any regulatory agency anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they said, adding that any product “falsely representing itself as a Lilly investigational product not yet approved … may expose users to possibly serious health risks”.
